ALTIERI, VINCENZO
 Distribuzione geografica
Continente #
NA - Nord America 368
EU - Europa 220
AS - Asia 177
AF - Africa 13
SA - Sud America 11
OC - Oceania 1
Totale 790
Nazione #
US - Stati Uniti d'America 363
SG - Singapore 89
IT - Italia 60
HK - Hong Kong 40
CN - Cina 39
UA - Ucraina 31
DE - Germania 24
RU - Federazione Russa 21
FI - Finlandia 20
IE - Irlanda 20
NL - Olanda 20
BR - Brasile 10
CI - Costa d'Avorio 10
SE - Svezia 9
VN - Vietnam 8
CA - Canada 5
ES - Italia 5
KE - Kenya 3
BE - Belgio 2
CZ - Repubblica Ceca 2
PL - Polonia 2
AR - Argentina 1
AT - Austria 1
AU - Australia 1
BG - Bulgaria 1
FR - Francia 1
GB - Regno Unito 1
IL - Israele 1
Totale 790
Città #
Singapore 58
Chandler 51
Hong Kong 40
Jacksonville 34
Ashburn 29
Santa Clara 26
Amsterdam 20
Naples 20
Princeton 15
Beijing 14
Boston 11
Millbury 10
Nanjing 9
Dong Ket 8
Los Angeles 8
Washington 7
Boardman 6
Milan 6
Wilmington 6
Dublin 5
Munich 5
Caserta 4
Helsinki 4
Nanchang 4
Ottawa 4
Changsha 3
Dearborn 3
Des Moines 3
Houston 3
Kronberg 3
Nairobi 3
Napoli 3
Norwalk 3
Aversa 2
Bologna 2
Brno 2
Courcelles 2
Cremona 2
Falls Church 2
Hebei 2
Oria 2
Adelaide 1
Augusta 1
Barcelona 1
Clifton 1
Concordia 1
Contagem 1
Council Bluffs 1
Cuggiono 1
Dallas 1
Falkenstein 1
Frankfurt am Main 1
Hefei 1
Jerusalem 1
Jiaxing 1
Madrid 1
Messina 1
Nova Iguaçu 1
Nürnberg 1
Orange 1
Orindiúva 1
Ribeauvillé 1
Rio de Janeiro 1
San Donato Milanese 1
Seattle 1
Shenyang 1
Simões Filho 1
Sofia 1
São Paulo 1
Tianjin 1
Turin 1
Vienna 1
Winnipeg 1
Totale 476
Nome #
Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol 81
Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer 61
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. 53
Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content. 52
Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients. 52
Modified glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical Cystectomy: A multicenter experience 48
Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading 47
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients 46
Soluble interleukin-6 receptor to interleukin-6 (sIL-6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy 45
Effects of the antidepressant St. John's wort (Hypericum perforatum) on rat and human vas deferens contractility 44
. 2009 Apr;20(4):. Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. 42
Not traditional prognostic factors in human conventional renal carcinoma. 39
Prevalence of silent prostatic adenocarcinoma in 165 patients undergone cystoprostatectomy: a retrospective study. 35
Galectin-1 And Galectin-3 Expression In Human Bladder Transitional Cell Carcinomas. 34
Ca vescicale 1995. 34
Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. 33
Ki67 in Gleason Pattern 3 as a Marker of the Presence of Higher-Grade Prostate Cancer 18
Amelanotic Malignant Melanoma of the Male Urethra: A Potential Diagnostic Pitfall 17
The best prostate biopsy sampling system—fusion and systematic biopsy: A single center experience 16
A serum metabolomic signature for the detection and grading of bladder cancer 13
KPNA2/ERG Coexpression is Associated with Early Recurrence in Advanced Prostate Cancers 12
Totale 822
Categoria #
all - tutte 4.021
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.021


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202024 0 0 0 0 0 0 0 0 0 3 14 7
2020/202168 0 6 8 6 10 4 6 0 7 5 8 8
2021/2022103 1 0 0 0 11 0 1 3 14 15 27 31
2022/2023158 15 2 10 5 24 19 0 12 36 26 7 2
2023/2024135 5 17 23 18 4 21 1 13 0 7 20 6
2024/2025205 25 8 9 9 26 29 65 34 0 0 0 0
Totale 822